Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents in Japanese patients with type 2 diabetes mellitus: a claims database analysis
Objectives To compare the risk of cardiovascular events from the initiation of therapy between metformin and dipeptidyl peptidase-4 inhibitors (DPP-4i) as first-line therapy.Design Retrospective cohort study using two claims databases.Setting The MDV database (provided by Medical Data Vision) compri...
Saved in:
| Main Authors: | Rimei Nishimura, Tomomi Takeshima, Kosuke Iwasaki, Sumiko Aoi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-03-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/3/e045966.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dipeptidyl peptidase-1 inhibitors in bronchiectasis
by: Emma Johnson, et al.
Published: (2025-06-01) -
SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
by: M. Ganeva
Published: (2023-03-01) -
Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
by: Taras S. Panevin, et al.
Published: (2020-12-01) -
The impact of oral semaglutide on glycemic control and weight reduction: a database analysis of dosing effects in Japanese individuals with type 2 diabetes
by: Mizuki Ishiguro, et al.
Published: (2025-08-01) -
Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus
by: Masashi Shimoda, et al.
Published: (2017-01-01)